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Abstract
Background: Endothelial progenitor cell (EPC) numbers are increased in septic patients and correlate with survival.
In this study, we investigated, whether surface expression of chemokine receptors and other receptors important
for EPC homing is upregulated by EPC from septic patients and if this is associated with clinical outcome.
Methods: Peripheral blood mononuclear cells from septic patients (n = 30), ICU control patients (n = 11) and healthy
volunteers (n = 15) were isolated by Ficoll density gradient centrifugation. FACS-analysis was used to measure the
expression of the CXC motif chemokine receptors (CXCR)-2 and − 4, the receptor for advanced glycation endproducts
(RAGE) and the stem cell factor receptor c-Kit. Disease severity was assessed via the Simplified Acute Physiology Score
(SAPS) II. The serum concentrations of vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF)-1α
and angiopoietin (Ang)-2 were determined with Enzyme linked Immunosorbent Assays.
Results: EPC from septic patients expressed significantly more CXCR-4, c-Kit and RAGE compared to controls and were
associated with survival-probability. Significantly higher serum concentrations of VEGF, SDF-1α and Ang-2 were found
in septic patients. SDF-1α showed a significant association with survival.
Conclusions: Our data suggest that SDF-1α and CXCR-4 signaling could play a crucial role in EPC homing in the
course of sepsis.
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Background
Endothelial barrier damage and dysfunction are core ele-
ments of sepsis pathophysiology. Without rapid restor-
ation of endothelial cell function, septic patients will
inevitably develop irreversible multi organ failure [1, 2].
In that respect, endothelial progenitor cells (EPC) might
constitute a potential targeted treatment option in the
future. It could be demonstrated, that EPC have the po-
tential to regenerate and reconstitute damaged endothe-
lial layers in several diseases like sepsis and acute
respiratory distress syndrome (ARDS) [3–7]. We and
others furthermore showed, that EPC in septic patients
are distinctly mobilized and that elevated EPC levels in
the circulation significantly correlate with survival in the
course of sepsis [7–10]. However, the molecular path-
ways that underlie EPC mediated endothelial barrier
regeneration in sepsis are still not well understood.
Endothelial progenitor cells are able to migrate into
damaged subendothelial layers, subsequently promote
angiogenesis and induce endothelial barrier regener-
ation, especially in states of systemic endothelial inflam-
mation [3]. This sequence must be preceded by a
directed EPC homing process [11]. The principal mecha-
nisms of cellular homing to endothelial sites of inflam-
mation are currently best examined in leukocytes [12]
and it can be assumed, that similar mechanisms also
influence EPC homing. Similar to leukocyte homing
EPC homing is a coordinated multi-step-process
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including mobilization, chemotaxis and attachment [13],
and its efficiency is influenced by the repertoire and the
level of chemokine expression by the target tissue as well
as the expression of the respective receptors on EPC
[14–21] Molecular regulators that affect both leukocyte
and EPC migration and activity are known and might
also play a potential role in EPC homing especially in sepsis.
The functional CXC-motive-chemokine receptor 4 (CXCR4)
and its ligand stromal cell derived factor 1α (SDF-1α), the re-
ceptor for advanced glycation endproducts (RAGE), the cell-
surface bound P-selectin ligand-1 (PSGL-1) and the CXC-
motive-chemokine receptor 2 (CXCR-2) have been demon-
strated to both impact leukocyte and EPC migration and
homing processes [11, 22–30]. Furthermore, the tyrosine-
kinase KIT (c-Kit) has been demonstrated to recruit
endothelial progenitor cells to inflamed endothelium [31]
and to modulate bone marrow derived progenitor cell
mobilization [32]. Additionally, vascular endothelial growth
factor (VEGF9) and Angiopoietin 2 (Ang210), the traditional
regulators of angiogenesis, are known EPC mobilizers and
inductors of EPC migration [33–35].
These mediators and their receptors could be import-
ant promoters or inhibitors of the EPC homing process
in sepsis and thereby influence the EPC mediated endo-
thelial regeneration in systemic inflammation. Thus, we
designed this clinical study, to primarily investigate
changes in the expression of CXCR-4, CXCR-2, RAGE,
c-Kit and PSGL-1 on EPC surfaces and to assess poten-
tial correlations with the serum levels of SDF-1α, VEGF
and Ang2 in septic patients.
Methods
Subjects
In our study, we included over a 3-year period patients with
sepsis from the ICU of the University Hospital Mannheim
within 48 h after onset of sepsis or at admission to the inten-
sive care unit. Included patients met the diagnostic criteria
for sepsis according to the American College of Chest Physi-
cians and the Society of Critical Care Medicine [36]. Disease
severity was measured on the basis of the Simplified Acute
Physiology Score II (SAPS II11) [37], and mortality was
defined as death occurring within 28 days after diagnosis.
Exclusion criteria were the use of statins or angiotensin-
converting enzyme inhibitors, the use of activated protein c,
the use hydrocortisone as well as cardiogenic or hemorrhagic
shock, chronic obstructive pulmonary disease, isolated acute
respiratory distress syndrome or the absence of mechanical
ventilation. We furthermore included ICU control patients
with need for mechanical ventilation as well as healthy con-
trols, which were volunteers from the laboratory staff. ICU
controls did not meet the criteria for sepsis, septic shock, or
systemic inflammatory response syndrome. The study was
approved by the Ethics Committee of the University of
Heidelberg. Approved and written informed consent was
obtained from all study subjects.
Blood sampling
20 ml blood obtained from septic patients was collected
within 24 h after sepsis onset. Blood from ICU control
patients was collected within 24 h after admission to the
ICU.
Isolation of peripheral blood mononuclear cells
Ficoll gradient centrifugation (Amersham Biosciences,
Freiburg, Germany) was used to isolate peripheral blood
mononuclear cells (PBMC) from the peripheral blood of
study subjects: Peripheral blood was diluted 1:2 with
phosphate buffered saline and gently layered on top of
the Ficoll solution. Centrifugation was performed at 20 °
C with 400 g for 30 min. Then, the cells in the inter-
phase were aspirated and centrifuged at 20 °C with
300 g for 15 min. The supernatant was discarded and
the pellet incubated with erythrocyte lysis buffer for
8 min. After that, the cells were washed two times with
phosphate buffered saline and centrifuged (20 °C with
300 g for 10 min). Thereafter, PBMC were prepared and
analyzed by flow cytometry.
Flow cytometry
The expression of cell-surface antigens was quantified by
immunostaining as described previously [7]. We used
the following monoclonal antibodies (anti-human): PE-
conjugated CD133 (Miltenyi Biotec, Bergisch-Gladbach,
Germany), PerCP-conjugated CD34 (BD Biosciences, Heidel-
berg, Germany), and either FITC-conjugated CXCR-4 or
APC-conjugated c-Kit, APC-conjugated CXCR-2 (all R&D
Systems, Wiesbaden-Nordenstadt, Germany), PE-conjugated
PSGL1 (BD Biosciences, Heidelberg, Germany) or the indir-
ect rabbit anti-human polyclonal RAGE antibody (Biozol,
Eching, Germany), for which a FITC-conjugated anti-rabbit
IgG antibody (Invitrogen, Karlsruhe, Germany) was used.
We used a FACSCalibur flow cytometer (BD Biosciences) for
flow cytometry. FACS-data analysis was performed with
WinMDI 2.8 software (Scripps Research Institute, La Jolla,
CA). EPC counts are expressed as percentage referred to
total PMBC in each study subject.
Enzyme-linked immunosorbent assay
VEGF, SDF-1α and Angiopoietin-2- serum concentrations
were measured with enzyme linked immunosorbent assay
kits in triplicate samples according to the instructions pro-
vided by the manufacturer (R&D Systems, Wiesbaden-
Nordenstadt, Germany).
Statistical analysis
All data were examined for normal and non-Gaussian
distribution by the Kolmogorov-Smirnov test. Results
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are presented as mean ± SD (Standard-Deviation). Both
parametric and nonparametric methods were used. For
comparison among normally distributed groups, one-
way ANOVA, followed by pairwise multiple comparison
(Student-Newman-Keuls method) was used. For non-
normally distributed data, the nonparametric Kruskal-
Wallis test followed by an all pairwise multiple compari-
son (Dunnett’s method) was used. We predicted survival
probability from EPC numbers based on logistic regres-
sion analysis. Pearson- Spearman correlation analyses
were considered for all target variables. P < 0.05 is con-
sidered to be statistically significant. All analyses were
performed using the SAS system (version 8.2).
Results
Patient population
In Table 1 relevant clinical data of the study patients
with regards to age, gender, mortality, SAPSII score, type
of infection, WBC count and PCT are summarized.
There was a significant increase of PCT levels (20-fold)
in sepsis patients compared to ICU patients (Table 1).
No significant differences in WBC and SAPSII values
were found between sepsis patients and ICU patients
(Table 1). Between survivors and non-survivors of the
sepsis group no significant differences in PCT levels,
WBC and SAPSII values were found (Additional file 1:
Table S1).
Endothelial progenitor cells in septic patients and
correlation with survival
The percentage of EPC was significantly increased by
120% in septic patients compared to ICU and by 190%
compared to healthy controls, while the difference in
EPC numbers between ICU and healthy controls was
smaller and not significant (Fig. 1) Within the group of
septic patients, sepsis survivors had increased numbers
of EPC compared to non-survivors by 28% (Fig. 1).
Logistic regression analysis revealed a significant influ-
ence of EPC number increase on survival probability
(odds ratio: 0,17, p = 0,037).
Chemokine and other receptors expressed by endothelial
progenitor cells
CXCR-4 expression on EPC from septic patients was sig-
nificantly increased by 69% compared to ICU controls
and by 22% compared to healthy controls (Fig. 2). In
contrast, CXCR-2 expression on EPC from septic
patients showed no significant difference compared to
ICU- or healthy controls (Fig. 2). The expression of
c-Kit on EPC from septic patients was significantly higher
compared to ICU- (increase by 47%) or healthy controls
(increase by 19%) (Fig. 2). The expression of RAGE on
EPC from septic patients was significantly higher
compared to ICU controls (increase by 38%) but not com-
pared to healthy controls (Fig. 2). The expression of
PSGL-1 on EPC from septic patients was comparable to
ICU patients and healthy controls (Fig. 2). CXCR-4, c-
Kit and RAGE expression in sepsis non-survivors was in-
creased compared to survivors, but these results were not
significant (Additional file 1: Figure S2). Logistic
regression analysis revealed, that CXCR-4 expression by
EPC increases the predictive value of EPC numbers on
survival probability in logistic regression analysis.
Serum concentration of the growth factors VEGF, SDF-1α
and Ang-2 is elevated in septic patients
Serum VEGF concentrations were significantly increased
in septic patients by 73% compared to ICU controls and
by 161% compared to healthy controls (Fig. 3a). Simi-
larly, also SDF-1α and Ang-2 concentrations were sig-
nificantly increased in septic patients compared to ICU
and healthy controls (Fig. 3c & 3e). There was no signifi-
cant difference in VEGF- and Ang2- serum concentra-
tions between sepsis survivors and sepsis non-survivors
(Fig. 3b & 3d). However, SDF-1α serum concentrations
were significantly increased in sepsis survivors compared
Table 1 Clinical characteristics of patients and controls
Characteristics Healthy controls ICU controls Septic patients
number of subjects 15 11 30
Age (years)
Mean ± SD 60,4 ± 14,3a 57,8 ± 14,2 35,8 ± 12,9
Gender
Male (%) 3 (20) 6 (54,5) 20 (66,6)
Female (%) 12 (80) 5 (45,5) 10 (33,3)
Mortality < 28 days (%) 0 (0) 15 (50)
Mean SAPS II score (range) 38,8 (15–59) 49,9 (22–74)





Gastrointestinal tract 3 (10)




WBC (×109/L) 10.5 15.5
PCT (ng/ml) 1,9 22,9a
Clinical data of study participants for age, gender, mortality, Simplified Acute
Physiology Score (SAPS) II score, type of infection, white blood cell (WBC) count
and procalcitonin (PCT) refer to the time point of blood sampling. aThe mean age
in the group of healthy controls was significantly lower compared to the patient
groups (p = 0.0001). There was no statistical difference in mean age between the
two patient groups (p= 0,61). There was a significant difference in PCT levels
between septic patients and ICU controls (p = 0,0002)
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to non-survivors (by 25%) (Fig. 3f ). For the entire study
population, a significant correlation between EPC num-
bers and serum levels of VEGF (r = 0.21, p = 0.03), SDF-
1α (r = 0.53, p = 0.001) and Ang-2 (r = 0.37, p = 0.0002)
was observed. There was also a positive correlation be-
tween EPC number and VEGF serum levels in the ICU
group (r = 0.42, p = 0.05) and the group of healthy con-
trols (r = 0.46, p = 0.02), while the EPC concentration in
septic patients or in the survivor/non-survivor sub-
groups was not correlated with serum VEGF, SDF-1α or
Ang-2 (Fig. 4).
Discussion
In this study we detected in septic patients an increase
of circulating EPC which expressed significantly more
CXCR-4, c-Kit and RAGE than EPC from non-septic
patients. Furthermore, the serum levels of SDF-1α were
significantly increased in both septic patients and survi-
vors of sepsis. EPC numbers showed to be associated
with sepsis survival probability. These findings indicate,
that the SDF-1α/CXCR-4 signalling might be involved in
EPC mediated regenerative processes during sepsis.
Several research groups including our own have dem-
onstrated, that septic patients and animals exhibit in-
creased levels of circulating EPC and that there is a
positive correlation with survival. EPC numbers have
been analysed and calculated in these studies using flow-
cytometry [7–10, 38]. However, in conflict with these
findings, studies based on colony forming assays for EPC
number analysis indicate, that EPC mobilization during
sepsis is not enhanced [39, 40]. Essentially, the reasons
behind these controversial findings still remain unre-
solved, but the differences in EPC purification- and
measurement methodologies might play a role. In our
study, we could again show a significant increase in EPC
numbers in septic patients compared to ICU controls
using flowcytometry. Thus, there are now multiple and
independent results available, which indicate that sepsis
leads to an increased mobilization of EPC into the per-
ipheral blood. In addition, our study results revealed a
positive influence of EPC numbers on sepsis survival
probability in linear regression analysis. This result is
also consistent with our previous findings and that of
others [7, 41].
Both EPC mobilization and EPC homing to damaged
endothelial layers are complex migratory processes,
which involve several adhesion molecules, chemoattrac-
tants and respective receptors, like CXCR-4, CXCR-2,
c-Kit, RAGE and PSGL-1 [14–21]. P-selectin glycoprotein
ligand-1 (PSGL-1) signaling can increase the pro-
Fig. 1 Numbers of circulating endothelial progenitor cells. a FACS analysis of CD34/CD133-positive cells in the peripheral blood mononuclear cell
fraction of healthy volunteers (n = 15), non-septic intensive care unit (ICU) patients (n = 11) and septic patients (n = 30). Significant differences
were found between the three groups. b FACS analysis of CD34/CD133-positive cells of septic patients, stratified for survival. Data are given as
mean ± SEM; * marks a significant difference (p < 0,05), # marks a significant influence on EPC on survival-probability in logistic regression analysis
including CXCR-4-expression as supressing variable (p = 0,037, odds ratio = 0,167)
Fig. 2 Upregulation of chemokine and other receptors by endothelial
progenitor cells. FACS analysis of the of CXCR-4, CXCR-2, c-Kit, RAGE and
PSGL-1 by CD34/CD133–positive cells in the peripheral blood mononuclear
cell fraction of healthy volunteers (n = 15), non-septic intensive care unit
(ICU) patients (n = 11) and septic patients (n = 30). * marks a significant
difference (p < 0,05). CXCR-4, CXC-motive-chemokine receptor 4; c-Kit,
tyrosine kinase KIT; CXCR-2, CXC-motive-chemokine receptor 2; RAGE,
receptor for advanced glycation products; PSGL-1, P-selectin ligand 1
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angiogenic potential of EPC [14] and is involved in neu-
trophil recruitment in an abdominal sepsis model [27].
A downregulation of the CXC-motive-chemokine
receptor-2 on neutrophils in severe sepsis impairs their
migratory properties [29]. CXCR-2 is also involved EPC
recruitment [30]. However, both PSGL-1 and CXCR-2
expression by EPC did not show significant differences
in comparison to ICU controls in our study. On the
contrary, we could demonstrate, that EPC from septic
patients exhibit a significantly increased expression of
the surface receptors CXCR-4, c-Kit and RAGE in com-
parison to EPC from ICU-controls and healthy con-
trols. The expression of CXCR-4 was already shown to
be increased on lymphocytes in sepsis [22] resulting in
improved migration and activation. Levels of its ligand
SDF-1α are also increased in septic states [23]. The
SDF-1α /CXCR-4 axis is furthermore involved in EPC
recruitment to the spleen [24] and CXCR-4 influences
EPC homing through cellular polarization [11]. The
receptor for advanced glycation endproducts RAGE is
expressed by several cells of the innate immune system
and activates NF-κ-B signaling [25]. RAGE signaling is
also involved in integrin dependent homing of EPC
[26]. The proto-oncogene c-Kit seems to play a crucial
role in EPC recruitment to inflamed endothelium: EPC
adhesion to tumor necrosis factor (TNF)-α treated
endothelial cells mediated via c-Kit involves the intra-
cellular Akt-pathway (Proteinkinase B, Akt) and can be
prevented, when pretreating EPC with the c-Kit inhibi-
tor imatinib [31]. Thus, the upregulation of CXCR-4,
c-Kit and RAGE by EPC shown in our study indicates,
that these factors could be important mediators of EPC
Fig. 3 Upregulation of mobilizing growth factors in serum. a Vascular endothelial growth factor (VEGF), (c) angiopoietin (Ang)-2 and (e) stromal cell-
derived factor 1α SDF-1α concentrations were detected in the serum of healthy volunteers (n = 15), non-septic intensive care unit (ICU) patients (n = 11)
and septic patients (n = 30). b, d, f The group of septic patients was also divided by survival and serum concentrations of the three mobilizing factors are
indicated. The results are expressed as ± SD; * marks a significant difference (p < 0,05)
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homing in sepsis. But CXCR-2 and PSGL-1 might
rather play minor roles in that respect.
Associated with the increased CXCR4 expression by
EPC from septic patients in our study, we could also de-
tect increased serum levels of the CXCR-4 ligand SDF-
1α in septic patients. This finding is consistent with pre-
vious publications [42]. Furthermore, we were also able
to show, that SDF-1α serum levels were significantly
higher in sepsis survivors compared to non-survivors.
Since the SDF-1α/CXCR-4-signalling axis impacts EPC
recruitment to peripheral tissues, according to our re-
sults it could also be involved in promoting EPC homing
in sepsis and thereby promote endothelial layer regener-
ation. In support of this Fan et al. found, that the syner-
gistic application of both VEGF and SDF-1α leads to an
increase of circulating EPC numbers and increased
survival in septic rats [43]. The application of CTCE-
0214, a SDF-1α peptide analog and CXCR-4 agonist,
significantly suppressed TNF and interleukin (IL)-10
concentrations and improved survival in murine
systemic inflammation [44] and sepsis [43].
Besides SDF-1α, we could also detect an increase of
VEGF and Ang2-serum levels in septic patients. A posi-
tive correlation of VEGF, Ang2 and SDF-1α with EPC
levels in septic patients compared to controls in our
study indicates an impact of those factors on
mobilization of EPC from the bone marrow during
sepsis as shown before [34, 45–47].
Our study underlies the limitation that there is
currently no unique single surface marker identified to
clearly detect and isolate the EPC phenotype when using
flowcytometry. However, culture based EPC purification
Fig. 4 FACS analysis data representative for each investigated group: healthy volunteers (a-e), ICU controls (f-j) and septic patients (k-o); histograms show the
percentage of CXCR-4, CXCR-2, c-Kit, RAGE and PSGL-1 expression in the population of CD34/CD133-positive cells. The dotted line in histograms represents
the negative control. APC, allophycocyanin; FITC, fluorescein; PE, phycoerythrin; CXCR-4, CXC-motive-chemokine receptor 4; c-Kit, tyrosine kinase KIT; CXCR-2,
CXC-motive-chemokine receptor 2; RAGE, receptor for advanced glycation products; PSGL-1, P-selectin ligand 1
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methods, even if they are simple to perform, often yield
heterogeneous cell populations, when analyzing surface
marker distributions with flowcytometry afterwards [48].
Via using the progenitor cell marker CD133 in our
FACS based EPC analysis, we could exclude mature
endothelial cells from EPC counting. However, our EPC
population counts likely include small amounts of
hematopoietic stem cells, since the classical definition of
EPC requires an endothelial marker protein like VEGF-R2
or CD31. Another limitation or our study arises from its
cross-sectional design, resulting in a lack of information
on EPC number changes or changes in surface receptor
expressions by EPC in the disease course of sepsis.
Conclusions
In conclusion, we have demonstrated here for the first
time that EPC in the clinical setting of sepsis exhibit a
high expression of CXCR-4, RAGE and c-Kit as potential
promoters of EPC homing. In concert with that the
serum level increase of the CXCR4-ligand SDF-1α was
closely associated with sepsis survival, as were EPC
numbers. Thus, our study provides first indications, that
the SDF-1α/CXCR-4 signalling axis might be involved in
EPC homing to damaged endothelial layers in sepsis,
which is the prerequisite step for further EPC based
regeneration processes. RAGE and c-Kit may also play
distinct roles in that respect. Further studies will have to
be performed to increase our understanding of the mo-
lecular pathways underlying EPC based barrier regener-
ation in sepsis in order to derive new targeted therapy
options in the future.
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